EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Selective somatostatin receptor 5 inhibition improves hepatic insulin sensitivity

Yumiko Okano Tamura iD, Jun Sugama, Shin-Ichi Abe, Yuji Shimizu, Hideki Hirose, Masanori Watanabe

Pharmacology Research & Perspectives · 2023

DOI: 10.1002/prp2.1043 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2023. Verfasst von Yumiko Okano Tamura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular and Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan. Hauptthemen laut MEDLINE: Insulin Resistance, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda Pharmaceutical Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes is a metabolic disorder with an increasing global prevalence. Somatostatin (SST), a peptide hormone, regulates hormone secretion via five SST receptor (SSTR) subtypes (SSTR1–5) in a tissue‐specific manner. As SSTR5 is expressed in pancreatic β‐cells and intestinal L‐cells, studies have suggested that SSTR5 regulates glucose tolerance through insulin and incretin secretion, thereby having a prominent role in diabetes. Moreover, SSTR5 knockout (KO) mice display enhanced insulin sensitivity; however, the underlying mechanism has not been clarified. Therefore, in this study, we investigate the effect of SSTR5 blockade on insulin resistance and the target organ using SSTR5 KO mice and a selective SSTR5 antagonist (compound‐1). High‐fat diet (HFD)‐fed SSTR5 KO mice exhibited significantly lower homeostasis model assessment of insulin resistance (HOMA‐IR) than HFD‐fed wild‐type mice. Two‐week oral administration of compound‐1 dose‐dependently and significantly reduced changes in the levels of glycosylated hemoglobin (GHb), plasma glucose, plasma insulin, and HOMA‐IR in male KK‐A y /Ta Jcl mice (KK‐A y mice), a model of obese type 2 diabetes with severe insulin resistance. Additionally, compound‐1 significantly increased the glucose infusion rate while decreasing hepatic glucose production in male KK‐A y mice, as evidenced by hyperinsulinemic‐euglycemic clamp analyses. In addition, compound‐1 ameliorated the insulin‐induced Akt phosphorylation suppression by octreotide in the liver of male C57BL/6J mice. Collectively, our results demonstrate that selective SSTR5 inhibition can improve insulin sensitivity by enhancing liver insulin action; thus, selective SSTR5 antagonists represent potentially novel therapeutic agents for type 2 diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Insulin ResistanceDiabetes Mellitus, Type 2MaleMiceAnimalsMice, Inbred C57BLInsulinGlucoseLiverMice, KnockoutReceptors, Somatostatin

Stichwörter der Autor:innen

SSTR5hepatic insulin resistancesomatostatintype 2 diabetes

Substanzen

InsulinGlucosesomatostatin receptor 5Receptors, Somatostatin

Autor:innen und Institutionen

  • Cardiovascular and Metabolic Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.
  • Biomolecular Research Laboratories, Takeda Pharmaceutical Company Limited, Fujisawa, Japan.

ORCID-Profile: Yumiko Okano Tamura

Förderung

  • Takeda Pharmaceutical Company

Zitieren

APA

Tamura, Y. O., Sugama, J., Abe, S. I., Shimizu, Y., Hirose, H., & Watanabe, M. (2023). Selective somatostatin receptor 5 inhibition improves hepatic insulin sensitivity. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.1043

Vancouver

Tamura YO, Sugama J, Abe SI, Shimizu Y, Hirose H, Watanabe M. Selective somatostatin receptor 5 inhibition improves hepatic insulin sensitivity. Pharmacology Research & Perspectives. 2023. doi:10.1002/prp2.1043

BibTeX
@article{Tamura2023,
  author = {Tamura, Yumiko Okano and Sugama, Jun and Abe, Shin-Ichi and Shimizu, Yuji and Hirose, Hideki and Watanabe, Masanori},
  title = {Selective somatostatin receptor 5 inhibition improves hepatic insulin sensitivity},
  journal = {Pharmacology Research & Perspectives},
  year = {2023},
  doi = {10.1002/prp2.1043}
}
Kostenlos starten →